2 news items
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
IVBIY
NUVB
2 Jun 24
and political, economic, legal and social conditions.
The Company, the Directors and the employees
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
IVBIY
NUVB
1 Jun 24
, the Company's competitive environment and political, economic, legal and social conditions.
The Company
- Prev
- 1
- Next